2026-04-17T19:22:59Zhttps://recercat.cat/oai/requestoai:recercat.cat:2445/1077532025-11-20T10:16:27Zcom_2072_1057col_2072_478809col_2072_478917
RECERCAT
author
Darbà, Josep
author
Ramírez, Gabriela
author
García-Rivero, Juan L.
author
Mayoralas, Sagrario
author
Pascual, José Francisco
author
Roger, Albert
author
Vargas, Diego
author
Bijedic, Adi
2017-03-02T15:37:24Z2017-03-02T15:37:24Z2016-092017-03-02T15:37:24Z
To assess the economic impact of the introduction of DuoResp(®) Spiromax(®) by focusing on a potential improvement in the inhalation technique to strengthen medication adherence for the treatment of moderate to severe asthmatics in Spain and five Spanish regions including Andalusia, Catalonia, Galicia, Madrid, and Valencia. ...
cc-by-nc (c) Darbà, Josep et al., 2016 http://creativecommons.org/licenses/by-nc/3.0/es info:eu-repo/semantics/openAccess
Administració de medicaments
Asma
Malalties pulmonars obstructives cròniques
Tractament tèrmic
Economia de la salut
Administration of drugs
Asthma
Chronic obstructive pulmonary diseases
Heat treatment
Medical economics
A budget impact analysis of Spiromax compared with Turbuhaler for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish Healthcare System and five Spanish regions
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion